Dr Mario Anthis interprets Menopause Plus within the MediBalans GCR (Global Constraint Rule) framework — a diagnostic hierarchical system that evaluates hormonal patterns in the context of nutrition, gut function and genetic methylation capacity.
The test maps the hormonal landscape so that treatment can address root causes rather than suppress symptoms. The estrogen pathways revealed in Menopause Plus determine whether the patient requires methylation correction, dietary recommendations or specific hormonal support.
Elevated 4-OH estrogen metabolites in Menopause Plus signal increased oxidative burden and potentially genotoxic risk. This information is combined with CYP1B1 and COMT genetics (WGS) and intracellular methylation capacity (CMA) to establish the primary constraint.